Drug intelligence / Profile preview

PHOENIX MOOD

Development stage: Preclinical
Lead developer: Phoenix Life Sciences
Modality: Small Molecules

Overview

PHOENIX MOOD is a plant-based pharmaceutical candidate developed by Phoenix Life Sciences for the treatment of anxiety and mood disorders. It is part of a suite of botanical-derived products aimed at various therapeutic areas, including mental health. While the company characterizes these products as pharmaceuticals, specific details regarding the active botanical constituents, molecular targets, and clinical trial phases are not publicly available. The product is positioned as a pharmaceutical-grade botanical intervention within the company's broader pipeline of plant-based therapies.

Brand names: PHOENIX MOOD

Beyond the preview

Go deeper on PHOENIX MOOD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PHOENIX MOOD.

Explore the full profile